Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Johnson & Johnson Innovation – Jjdc Inc.
BioCentury | Mar 12, 2025
Product Development
Oral peptide win for Protagonist/J&J, Beam’s base editor POC, and more: Clinical Report
Protagonist data led to week’s biggest share price gain, while Arvinas saw biggest loss: in BioCentury’s latest Clinical Report
BioCentury | Mar 10, 2025
Deals
Sun takes shine to Checkpoint in $355M buyout: Deals Report
Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
BioCentury | Mar 1, 2025
Data Byte
EMA’s CHMP reaffirms its decision to back Leqembi for Alzheimer’s
Regeneron’s bispecific, Krystal’s gene therapy, and 16 label extensions also among positive opinions issued at committee’s February meeting
BioCentury | Feb 25, 2025
Management Tracks
After leaving FDA, Cavazzoni joins Pfizer as CMO
Plus: CFO hires at Nuclera, Crinetics, Terns and updates from Xeris, Inhibikase and Climb Bio
BioCentury | Feb 20, 2025
Product Development
Solid produces best-in-class biomarker data among DMD gene therapies
BioCentury’s latest Clinical Report highlights a pair of value-driving readouts
BioCentury | Feb 13, 2025
Emerging Company Profile
Unnatural: Expanding the macrocyclic peptide chemical space
Company applying small molecule optimization techniques to peptides with a robotic synthesis platform
BioCentury | Feb 6, 2025
Management Tracks
Arcturus appoints Slaoui chair designate
Plus: Affinia hires Makimura and Xu joins Sciwind
BioCentury | Jan 31, 2025
Product Development
Precision neuropsychiatry spotlight: a BioCentury podcast
Plus: Insights from Icon’s Peter Schueler on the ECNP Roadmap Meeting on Precision Psychiatry
BioCentury | Jan 30, 2025
Market Access
PBMs limiting Part D coverage of generics
New analysis by Avalere could be used to support PBM reform
BioCentury | Jan 29, 2025
Guest Commentary
Winning over Wall Street: Biotechs’ comeback playbook — a Guest Commentary by Jami Rubin
Advice for CEOs and CFOs as they navigate the year ahead
Items per page:
1 - 10 of 11104